The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 7, 2017

Study Completion Date

December 31, 2017

Conditions
Pancreaticoduodenectomy
Interventions
DRUG

Norzyme® 40000 IU

A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal

DRUG

Placebo

Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.

Trial Locations (6)

463-707

Seoul National University Bundang Hospital, Seongnam

410-769

Center for Liver Cancer, National Cancer Center, Goyang-si

410-773

Dongguk University Ilsan Medical Center, Goyang

110-744

Department of Surgery, Seoul National University College of Medicine, Seoul

156-755

Chung-Ang University Hospital, Seoul

Unknown

Kangnam Severance Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pharmbio Korea Co., Ltd.

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02127021 - The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy | Biotech Hunter | Biotech Hunter